Acknowledgments
This study was sponsored by Eisai Co., Ltd. Nivolumab was provided by Ono Pharmaceutical Co., Ltd. Medical writing support was provided by Michael Venditto, PharmD, of Oxford PharmaGenesis Inc., and was funded by Eisai Inc.
